Trinabol 150 mg is an oil-based tri-trenbolone blend injectable manufactured by British Dragon and dosed at 150 mg/mL in a 10 mL vial. It combines three trenbolone esters — acetate, enanthate, and hexahydrobenzylcarbonate — in a single formulation.
Trinabol 150 mg contains a three-ester trenbolone blend designed to provide both rapid and extended release of trenbolone after administration. Trenbolone is a synthetic anabolic steroid that has never been approved by the FDA for human use and is classified as a Schedule III controlled substance. It is used in veterinary medicine as an implant to promote muscle growth in cattle.
In non-medical bodybuilding contexts, tri-trenbolone blends are commonly referenced for their potent effects on body composition. The inclusion of trenbolone acetate provides a rapid initial release, while the longer-acting enanthate and hexahydrobenzylcarbonate esters extend the duration of activity. This multi-ester design is intended to produce a more stable blood level of trenbolone than a single-ester preparation, though the practical benefits of this approach are debated among experienced users.
Trenbolone binds to the androgen receptor with high affinity and does not aromatize to estrogen. However, it is known for a distinctive side effect profile that may include insomnia, night sweats, increased aggression, and cardiovascular stress. The hexahydrobenzylcarbonate ester was formerly marketed for human use under the brand name Parabolan but was discontinued in 1997. Non-medical use of trenbolone falls outside approved indications and carries significant health risks.
Trinabol 150 mg uses MCT oil as its carrier oil, providing the oil base for the three-ester trenbolone blend.
The three-ester formulation of Trinabol 150 mg is designed to combine the pharmacokinetic characteristics of short-, medium-, and long-acting trenbolone esters into a single injectable preparation.
Each ester in Trinabol 150 mg influences how quickly trenbolone is released from the injection site. Trenbolone acetate is a short-acting ester with a half-life of approximately one to two days, contributing to a rapid increase in serum trenbolone after injection. Trenbolone hexahydrobenzylcarbonate is a longer-acting ester with a half-life reported in the range of three to seven days depending on the source. Trenbolone enanthate occupies a similar long-acting position with an estimated half-life of approximately eight to ten days.
The rationale for blending these esters is to provide an initial surge of trenbolone from the short-acting component followed by sustained release from the longer-acting components. This design is intended to reduce the frequency of injections compared to using trenbolone acetate alone, while still providing a more rapid onset than a single long-acting ester. However, some experienced users have noted that the differing half-lives make it more difficult to time a dosing schedule compared to using a single ester.
Once the esters are metabolized, the active compound in all cases is trenbolone. The ester primarily determines the rate of release and duration of activity rather than changing the underlying properties of trenbolone itself.
Trinabol 150 mg is designed to provide both a rapid initial increase in trenbolone and a prolonged elevation between injections. The acetate ester contributes to the faster component, while the enanthate and hexahydrobenzylcarbonate esters support the extended-release component. This multi-ester design distinguishes it from single-ester trenbolone preparations.
British Dragon offers several trenbolone formulations built around different esters and release profiles. The main practical distinction between these preparations is how quickly trenbolone is released and how long the formulation remains active after administration.
Trinabol 150 mg is a multi-ester blend, whereas Trenabol 100 (trenbolone acetate) and Trenabol Depot (trenbolone enanthate) are single-ester preparations. Trenabol Hexa provides trenbolone hexahydrobenzylcarbonate as a standalone ester. The blend format of Trinabol 150 mg is intended to combine the characteristics of these individual preparations.
The information below is provided for educational reference only. Trenbolone has not been approved by the FDA for human use. Non-medical use falls outside approved indications and carries significant health risks.
In non-medical bodybuilding contexts, tri-trenbolone blends such as Trinabol 150 mg are commonly referenced in the range of 150–300 mg per week. Because the blend contains the short-acting acetate ester, injection frequency of at least every other day is commonly referenced to take advantage of the fast-acting component. Some experienced users reference 150–250 mg per week as a moderate range. Cycle duration is typically referenced as 6–8 weeks due to the compound's harsh side effect profile.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Bodybuilding (non-medical, moderate) | 150–200 mg / week | Every other day or 3x weekly |
| Bodybuilding (non-medical, experienced) | 200–300 mg / week | Every other day or daily |
| Stacking with testosterone | Typically combined with a testosterone base | Per cycle protocol |
In non-medical bodybuilding contexts, tri-trenbolone blends are often stacked with testosterone as a base compound. The "Test & Tren" stack is commonly referenced, with trenbolone at 150–300 mg per week alongside a testosterone base. British Dragon offers several testosterone preparations that are commonly referenced in this context, including Testabol Propionate and Sustabol 350.
Trenbolone is considered an advanced compound, and many resources emphasize that it should be used cautiously or not at all due to its significant side effect profile. Cycle structure, duration, and support compounds should be considered in the context of individual experience and health status.
Trenbolone is known for a distinctive set of side effects that differ from many other anabolic steroids. Commonly reported effects include insomnia, night sweats, increased aggression, anxiety, and cardiovascular stress. A recent review noted that 90% of trenbolone users experience injurious side effects, with severe acne and gynecomastia affecting approximately one-third of users.
Because trenbolone does not aromatize, aromatase inhibitors are not relevant for managing its side effects. Some users reference cabergoline for prolactin-related effects, though this should be based on bloodwork and medical guidance. Cardiovascular health, including lipid profiles, should be monitored during use.
After completing a cycle with Trinabol 150 mg, post-cycle therapy is commonly recommended to help restore endogenous testosterone production and support hormonal recovery. Agents such as Clomiphene and Tamoxifen are commonly referenced for this purpose.
Because the blend contains longer-acting esters, it takes longer to clear from the system than trenbolone acetate alone. PCT protocols vary based on cycle length, compounds used, and individual factors.
Dosing strategies, support compounds, and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Trenbolone has not been approved by the FDA for human use. It is classified as a Schedule III controlled substance. Non-medical use carries significant health risks.
Trenbolone is a veterinary anabolic steroid that has never been approved for human use. The NIH PubChem database classifies trenbolone as a reproductive toxicant (Repr. 1A) based on aggregated GHS information from multiple notifications. The FDA has approved trenbolone only as an implant for cattle to increase weight gain.
Anabolic steroids, including trenbolone, have not been shown to enhance athletic ability. Non-medical use of tri-trenbolone blends falls outside approved indications and is associated with significant health risks.
Trenbolone has not been approved for human use. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual. The risks associated with trenbolone use are significant and may include cardiovascular, neurological, and hepatic effects.
A 2024 review of trenbolone's effects on selected organs noted that 90% of users experience injurious side effects. Commonly reported effects include insomnia, night sweats, increased aggression, anxiety, and cardiovascular stress. Severe acne and gynecomastia affect approximately one-third of all users.
Anabolic steroids can affect lipid profiles, typically reducing HDL cholesterol and potentially increasing LDL cholesterol. Trenbolone is noted for being notably harsh on cardiovascular health. Excessive body hair, stretch marks, hypertension, and cardiac arrhythmia have also been reported.
Androgenic effects such as acne, oily skin, and hair loss in predisposed individuals can occur. Women may experience virilization symptoms including voice deepening, clitoral enlargement, and menstrual irregularities, and this drug should not be taken by females.
The drugs are also subject to contamination, with use frequently resulting in local inflammation at the injection site, muscle adhesions and fibrosis, nerve damage or, in extreme cases, necrosis of the injection site.
Trenbolone is not appropriate for individuals with certain medical conditions. Medical evaluation should precede any consideration of use, particularly for those with existing cardiovascular disease, liver conditions, or a history of hormone-sensitive cancers.
Pregnancy and breastfeeding are absolute contraindications. Women considering use should be aware of the potential for irreversible virilization effects.
Medically supervised anabolic steroid therapy involves regular monitoring of liver function, lipid profiles, and hormone levels. However, because trenbolone has not been approved for human use, there are no established monitoring protocols for its non-medical use. Bloodwork can help identify adverse changes, but the absence of monitoring significantly increases the risk of unrecognized adverse effects.
Keep the vial securely stored and protected from conditions that could compromise the product or container. Inspect the vial and solution before use and do not use a product that appears damaged, contaminated, or otherwise abnormal.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Trinabol 150 mg is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official British Dragon distribution chain.
To verify your Trinabol 150 mg product, use the security features on the vial label and cross-check them with official British Dragon presentation. Genuine British Dragon vials typically feature specific label characteristics and packaging details that distinguish them from counterfeits.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at controlled room temperature (15–25°C) and protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the oily formulation.
Keep the vial in its original packaging until use. Do not freeze. Before administration, inspect the solution and avoid use if it appears cloudy, discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Trinabol 150 mg, the three-ester trenbolone blend, usage, and related topics.
Trinabol 150 mg contains a three-ester trenbolone blend. Trenbolone has not been approved by the FDA for human use and is classified as a Schedule III controlled substance. In non-medical bodybuilding settings, Trinabol 150 mg is commonly referenced for cutting and recomposition due to its potent effects, though such use falls outside approved indications and carries significant health risks.
Because Trinabol 150 mg contains trenbolone acetate, a short-acting ester, injection frequency of at least every other day is commonly referenced to take advantage of the fast-acting component. Some users reference three-times-weekly administration. Injection frequency should be based on individual factors and experience level.
Trenbolone can suppress endogenous testosterone production. In non-medical bodybuilding contexts, post-cycle therapy is commonly referenced after a cycle to support hormonal recovery. Agents such as Clomiphene and Tamoxifen are commonly discussed for this purpose. Because the blend contains longer-acting esters, PCT may need to be delayed compared to shorter-acting trenbolone preparations.
The three trenbolone esters in Trinabol 150 mg release trenbolone at different rates after injection. The acetate ester acts quickly, while the enanthate and hexahydrobenzylcarbonate esters provide a slower, more sustained release. The active compound in all cases is trenbolone, which binds to androgen receptors with high affinity and does not aromatize to estrogen.
The acetate component of Trinabol 150 mg is released relatively quickly after injection. The longer-acting esters provide sustained release over a longer period. Visible effects on physique and performance are typically referenced as taking several weeks to become apparent, depending on dose, diet, training, and individual factors. Cycle duration is typically referenced as 6–8 weeks.
There is no single trenbolone preparation that is universally best. Multi-ester blends such as Trinabol 150 mg are designed to provide both rapid and extended release, while single-ester preparations offer more predictable release characteristics. Some experienced users prefer single esters for easier dosing schedule management. The appropriate formulation depends on individual circumstances.
Trinabol 150 mg is a three-ester blend, while Trenabol 100 contains only trenbolone acetate. The blend is designed to provide both fast and slow release of trenbolone, whereas acetate provides a more rapid onset and faster clearance. Some users prefer the acetate version because it clears the system more quickly if side effects occur.
Trinabol 150 mg contains three trenbolone esters including the short-acting acetate, while Trenabol Depot contains only trenbolone enanthate. The blend is designed to provide a more rapid onset than the single long-acting ester, while still offering extended release from the longer-acting components.
A milligram amount cannot be classified as appropriate or excessive without considering individual factors, experience level, and side effect tolerance. In bodybuilding contexts, 150–300 mg per week falls within commonly referenced ranges, but this does not establish that it is safe or appropriate for any individual. Non-medical use falls outside approved indications.
Trinabol 150 mg is labeled at 150 mg of total trenbolone esters per mL, comprising trenbolone acetate 50 mg, trenbolone enanthate 50 mg, and trenbolone hexahydrobenzylcarbonate 50 mg. It is supplied in a 10 mL vial, giving 1,500 mg of total labeled trenbolone content per vial.
No. Trenbolone does not aromatize to estrogen, meaning it is not associated with estrogenic side effects such as gynecomastia or water retention. However, it is known for a different set of side effects that may include insomnia, night sweats, and cardiovascular stress.